secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001193805-23-000401
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q4 2022 net income $117.3M ($4.33/diluted share), revenue surge to $160.3M on CSL deal
--------------------------------------------------------------------------------

- Q4 2022 revenue $160.3M vs $5.8M same quarter 2021; full-year revenue $206.0M vs $12.4M.
- Recorded net income $117.3M ($4.33/diluted) for Q4 vs net loss $38.7M ($1.47 loss) prior year.
- Received $200M upfront from CSL Seqirus in Dec 2022; $90M milestones invoiced in Mar 2023.
- Cash $391.9M at Dec 31, 2022; repaid $17.1M to Singapore, eliminating $33.3M non-recourse debt.
- ARCT-154 Phase 3 booster fully enrolled in Japan; ARCT-810 Phase 2 interim data expected later 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523000401/0001193805-23-000401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523000401/e618402_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-000401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer